BRPI9801092A - processo para a produção de fator recombinante viii e meio de cultura de célula. - Google Patents

processo para a produção de fator recombinante viii e meio de cultura de célula.

Info

Publication number
BRPI9801092A
BRPI9801092A BRPI9801092A BRPI9801092A BRPI9801092A BR PI9801092 A BRPI9801092 A BR PI9801092A BR PI9801092 A BRPI9801092 A BR PI9801092A BR PI9801092 A BRPI9801092 A BR PI9801092A BR PI9801092 A BRPI9801092 A BR PI9801092A
Authority
BR
Brazil
Prior art keywords
factor viii
recombinant factor
production
culture medium
cell culture
Prior art date
Application number
BRPI9801092A
Other languages
English (en)
Inventor
Sham-Yuen Chan
Kathleen Harris
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25293446&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI9801092(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of BRPI9801092A publication Critical patent/BRPI9801092A/pt
Publication of BRPI9801092B1 publication Critical patent/BRPI9801092B1/pt
Publication of BRPI9801092B8 publication Critical patent/BRPI9801092B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/35—Polyols, e.g. glycerin, inositol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C12N2500/95—Protein-free medium and culture conditions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

patente de invenção: <b>"preparação de fator recombinante viii em um meio isento de proteína"<d>. fator viii recombinante pode ser produzido em quantidades relativamente grandes em uma base contínua a partir de células de mamíferos na ausência de quaisquer proteínas derivadas de animal tal como albumina pelo cultivo das células em um meio isento de proteína suplementado com copolímeros de poliol, de preferência na presença de traços de metais tal como cobre. em modelidades muito preferidas, o meio inclui um poliglicol conhecido como pluronic f-68, sulfato de cobre, complexo sulfato ferroso/edta e sais de metais em traços tais como manganês, molibdênio, silício, lítio e cromo.
BRPI9801092-1 1997-04-18 1998-04-17 processo para a produÇço de fator recombinante viii e meio de cultura de cÉlula. BRPI9801092B8 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/844,714 US5804420A (en) 1997-04-18 1997-04-18 Preparation of recombinant Factor VIII in a protein free medium

Publications (3)

Publication Number Publication Date
BRPI9801092A true BRPI9801092A (pt) 2000-01-11
BRPI9801092B1 BRPI9801092B1 (pt) 2013-04-02
BRPI9801092B8 BRPI9801092B8 (pt) 2021-07-06

Family

ID=25293446

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9801092-1 BRPI9801092B8 (pt) 1997-04-18 1998-04-17 processo para a produÇço de fator recombinante viii e meio de cultura de cÉlula.

Country Status (28)

Country Link
US (2) US5804420A (pt)
EP (1) EP0872487B1 (pt)
JP (1) JP4257685B2 (pt)
KR (1) KR100496111B1 (pt)
CN (1) CN1127518C (pt)
AR (1) AR012451A1 (pt)
AT (1) ATE342921T1 (pt)
AU (1) AU748731B2 (pt)
BR (1) BRPI9801092B8 (pt)
CA (1) CA2234215C (pt)
CO (1) CO4790112A1 (pt)
CZ (1) CZ295049B6 (pt)
DE (1) DE69836164T2 (pt)
DK (1) DK0872487T3 (pt)
ES (1) ES2273380T3 (pt)
HU (1) HU224306B1 (pt)
ID (1) ID20193A (pt)
IL (1) IL124123A (pt)
MY (1) MY115583A (pt)
NZ (1) NZ330183A (pt)
PL (1) PL192072B1 (pt)
PT (1) PT872487E (pt)
RU (1) RU2222547C2 (pt)
SK (1) SK285684B6 (pt)
TR (1) TR199800493A1 (pt)
TW (1) TW490469B (pt)
UA (1) UA66340C2 (pt)
ZA (1) ZA983234B (pt)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501040D0 (en) * 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
US8183344B2 (en) * 1996-04-24 2012-05-22 University Of Michigan Inactivation resistant factor VIII
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US6528286B1 (en) * 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
AUPP521298A0 (en) * 1998-08-12 1998-09-03 Life Therapeutics Limited Purification of fibrinogen
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
AUPP790698A0 (en) 1998-12-23 1999-01-28 Life Therapeutics Limited Separation of microorganisms
US20050224355A1 (en) * 1999-12-23 2005-10-13 Brendon Conlan Removal of biological contaminants
AUPP790898A0 (en) 1998-12-23 1999-01-28 Life Therapeutics Limited Renal dialysis
AUPP971399A0 (en) 1999-04-12 1999-05-06 Life Therapeutics Limited Separation of plasma components
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
DE60024268T2 (de) * 1999-07-13 2006-08-03 Biovitrum Ab Zusammensetzungen mit stabilem faktor viii
US6767741B1 (en) * 1999-08-27 2004-07-27 Invitrogen Corporation Metal binding compounds and their use in cell culture medium compositions
EP1144060B1 (en) 1999-08-31 2009-02-18 Sony Computer Entertainment Inc. Entertainment system, recording medium, and program
US7077942B1 (en) * 1999-12-23 2006-07-18 Gradipore Limited Removal of biological contaminants
AUPQ691400A0 (en) 2000-04-14 2000-05-11 Life Therapeutics Limited Separation of micromolecules
AUPQ697300A0 (en) 2000-04-18 2000-05-11 Life Therapeutics Limited Separation apparatus
WO2001078877A1 (en) 2000-04-18 2001-10-25 Gradipore Limited Electrophoresis separation and treatment of samples
US6923896B2 (en) * 2000-09-22 2005-08-02 The Texas A&M University System Electrophoresis apparatus and method
JP2004510170A (ja) * 2000-10-06 2004-04-02 グラディポア　リミテッド マルチポート型分離装置および方法
AUPR222300A0 (en) * 2000-12-21 2001-01-25 Life Therapeutics Limited Electrophoresis device and method
US7220718B2 (en) 2001-08-03 2007-05-22 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Oral treatment of hemophilia
ES2411007T3 (es) 2001-10-10 2013-07-04 Novo Nordisk A/S Remodelación y glicoconjugación de péptidos
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
EP1458408B1 (en) 2001-12-21 2009-04-15 Novo Nordisk Health Care AG Liquid composition of factor vii polypeptides
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
CN1671410B (zh) 2002-06-21 2010-05-12 诺和诺德医疗保健公司 因子ⅶ多肽的稳定化固体组合物
EP2287288B1 (en) 2002-07-09 2012-11-07 Baxter International Inc. Animal protein free media for cultivation of cells
BRPI0407882B1 (pt) * 2003-02-26 2021-07-27 Nektar Therapeutics Composição compreendendo conjugados de polímero-porção de fator viii e seu método de fabricação
AU2004222625A1 (en) * 2003-03-18 2004-09-30 Novo Nordisk Health Care Ag Liquid, aqueous, pharmaceutical compositions of factor VII polypeptides
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
RU2364609C2 (ru) * 2003-05-23 2009-08-20 Ново Нордиск Хелт Кэр Аг Стабилизация белка в растворе
EP1641487B1 (en) * 2003-06-25 2012-02-29 Novo Nordisk Health Care AG Liquid composition of factor vii polypeptides
WO2005002615A1 (en) * 2003-07-01 2005-01-13 Novo Nordisk Health Care Ag Liquid, aqueous pharmaceutical composition of factor vii polypeptides
JP5653572B2 (ja) * 2003-08-14 2015-01-14 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液状水性医薬組成物
CN1917861B (zh) * 2003-12-19 2012-03-21 诺和诺德医疗保健公司 因子vii多肽的稳定化固体组合物
GB0414825D0 (en) 2004-07-02 2004-08-04 Biostatus Ltd Gel formulations and uses thereof
US7422875B2 (en) * 2004-07-20 2008-09-09 Board Of Regents Of The University Of Nebraska Compositions and methods for increasing protein production
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
AU2005302516A1 (en) * 2004-10-29 2006-05-11 Centocor, Inc. Chemically defined media compositions
GT200600027A (es) * 2005-01-25 2006-08-31 Protectores contra el esfuerzo cortante en la microfiltracion de la cosecha
EP1707634A1 (en) * 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins
ES2474573T3 (es) * 2006-01-04 2014-07-09 Baxter International Inc Medio de cultivo celular sin oligop�ptidos
US20090203077A1 (en) * 2006-06-30 2009-08-13 The Regents Of The University Of Michigan Method of producing factor viii proteins by recombinant methods
CA2656558A1 (en) * 2006-06-30 2008-01-10 The Regents Of The University Of Michigan Method of producing factor viii proteins by recombinant methods
HUE035243T2 (hu) * 2007-02-23 2018-05-02 Sk Chemicals Co Ltd Eljárás VIII. faktor és származékainak elõállítására és tisztítására
CA2683317C (en) * 2007-04-26 2014-12-16 Bayer Healthcare Llc Stabilization of liquid solutions of recombinant protein for frozen storage
CN101965409A (zh) * 2007-11-01 2011-02-02 罗切斯特大学 具有增加的稳定性的重组因子viii
SG187397A1 (en) 2007-12-27 2013-02-28 Baxter Int Cell culture processes
DE102008051574A1 (de) 2008-10-14 2010-04-15 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zur Herstellung von Interferon-beta und deren Varianten
PT2356247E (pt) * 2008-11-12 2015-10-26 Baxalta Inc Método de produção de fator vii isento de soro e de insulina
CN104962539B (zh) 2009-07-31 2019-09-17 百深公司 用于adamts蛋白表达的细胞培养基
PL4218797T3 (pl) 2009-09-21 2025-02-10 Takeda Pharmaceutical Company Limited Stabilizowane płynne i liofilizowane preparaty adamts13
WO2011060242A2 (en) 2009-11-13 2011-05-19 Talecris Biotherapeutics, Inc. Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto
CA2797356C (en) 2010-04-26 2020-12-29 Novartis Ag Improved cell culture medium
WO2012006594A1 (en) 2010-07-08 2012-01-12 Baxter International Inc. Method of producing recombinant adamts13 in cell culture
GB201014121D0 (en) * 2010-08-24 2010-10-06 Univ Gent Particulate biologic drug delivery system
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
CN105189735B (zh) * 2011-04-29 2019-04-12 拜康研究有限公司 在培养期间减少乳酸累积的方法和生产多肽的方法
ES2970057T3 (es) 2011-05-13 2024-05-24 Octapharma Ag Un procedimiento para aumentar la productividad de células eucarióticas en la producción de FVIII recombinante
WO2013098676A1 (en) 2011-12-30 2013-07-04 Grifols, S.A. Method for purifying factor viii
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
HK1207960A1 (en) 2013-03-12 2016-02-19 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US20140271622A1 (en) * 2013-03-14 2014-09-18 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9677105B2 (en) 2013-03-14 2017-06-13 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2015143512A2 (en) * 2014-03-23 2015-10-01 Advantech Bioscience Farmacêutica Ltda. Enhancement of recombinant protein expression with copper
HRP20200372T1 (hr) 2014-03-25 2020-06-12 F. Hoffmann - La Roche Ag Postupci proizvodnje poloksamera za upotrebu u mediju za staničnu kulturu
US9855319B2 (en) 2014-04-01 2018-01-02 Advantech Bioscience Farmacêutica Ltda Stabilization of factor VIII without calcium as an excipient
JP2017509659A (ja) 2014-04-01 2017-04-06 アドヴァンテック・バイオサイエンス・ファルマスーティカ・リミターダ 低糖−低グリシンの安定な第ｖｉｉｉ因子製剤
WO2017195745A1 (ja) * 2016-05-09 2017-11-16 国立研究開発法人医薬基盤・健康・栄養研究所 培地、アルブミン非含有培地用添加剤および多能性幹細胞の培養方法
WO2018210771A1 (en) * 2017-05-17 2018-11-22 Octapharma Ag Method for the production of a recombinant target protein
EP3781941B1 (en) 2018-04-20 2026-01-14 Janssen Biotech, Inc. Chromatography column qualification in manufacturing methods for producing anti-tnf antibody compositions
EA202191352A1 (ru) 2018-11-13 2021-08-11 Янссен Байотек, Инк. Контроль содержания микроэлементов-металлов во время продукции антител к cd38
EP3938384A4 (en) 2019-03-14 2022-12-28 Janssen Biotech, Inc. PREPARATION PROCEDURES FOR THE PREPARATION OF ANTI-IL12/IL23 ANTIBODY COMPOSITIONS
WO2020183269A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
EA202192505A1 (ru) 2019-03-14 2022-03-29 Янссен Байотек, Инк. Способы получения композиций антитела к фно
KR20210141998A (ko) 2019-03-14 2021-11-23 얀센 바이오테크 인코포레이티드 항-tnf 항체 조성물의 제조 방법
SG11202110968VA (en) 2019-12-06 2021-10-28 Regeneron Pharma Anti-vegf protein compositions and methods for producing the same
US20230203469A1 (en) 2020-04-02 2023-06-29 Takeda Pharmaceutical Company Limited Adamts13 variant, compositions, and uses thereof
AU2021268026A1 (en) 2020-05-08 2023-01-19 Regeneron Pharmaceuticals, Inc. VEGF traps and mini-traps and methods for treating ocular disorders and cancer
JP2024527581A (ja) 2021-07-09 2024-07-25 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ１２／ｉｌ２３抗体組成物を生産するための製造方法
US12534524B2 (en) 2021-07-09 2026-01-27 Janssen Biotech, Inc. Manufacturing methods for producing anti-TNF antibody compositions
CN119301236A (zh) 2022-03-02 2025-01-10 瑞泽恩制药公司 用于抗体生产的生物反应器
WO2024228717A2 (en) 2022-09-07 2024-11-07 Quantitative Biosciences, Inc. Fentanyl-specific single variable-domain antibodies and use in a continuous agglutination assay
WO2025128343A1 (en) 2023-12-11 2025-06-19 Just-Evotec Biologics, Inc. Protein expression using trans-splicing and split selectable markers
WO2026058210A1 (en) 2024-09-12 2026-03-19 Janssen Biotech, Inc. Model system and biomarkers to prevent lactate runaway

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440679A (en) * 1980-03-05 1984-04-03 Cutter Laboratories, Inc. Pasteurized therapeutically active protein compositions
US4767704A (en) * 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US5576194A (en) * 1986-07-11 1996-11-19 Bayer Corporation Recombinant protein production
NO162160C (no) * 1987-01-09 1989-11-15 Medi Cult As Serumfritt vekstmedium, samt anvendelse derav.
US5024947A (en) * 1987-07-24 1991-06-18 Cetus Corporation Serum free media for the growth on insect cells and expression of products thereby
JPH0387173A (ja) * 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
US5378612A (en) * 1990-05-11 1995-01-03 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Culture medium for production of recombinant protein
CA2078721A1 (en) * 1991-09-24 1993-03-25 Hiroshi Yonemura Process for preparing human coagulation factor viii protein complex
US6103529A (en) * 1996-10-10 2000-08-15 Life Technologies, Inc. Animal cell culture media comprising peptides derived from rice

Also Published As

Publication number Publication date
HUP9800901A3 (en) 2001-08-28
AR012451A1 (es) 2000-10-18
KR19980081531A (ko) 1998-11-25
EP0872487A3 (en) 1999-10-27
DE69836164D1 (de) 2006-11-30
CN1210866A (zh) 1999-03-17
CO4790112A1 (es) 1999-05-31
CA2234215C (en) 2008-06-17
PL325862A1 (en) 1998-10-26
IL124123A (en) 2006-07-05
ES2273380T3 (es) 2007-05-01
AU748731B2 (en) 2002-06-13
DK0872487T3 (da) 2007-02-05
BRPI9801092B1 (pt) 2013-04-02
ID20193A (id) 1998-10-22
KR100496111B1 (ko) 2005-09-09
EP0872487A2 (en) 1998-10-21
DE69836164T2 (de) 2007-08-16
TR199800493A1 (xx) 1998-11-23
CN1127518C (zh) 2003-11-12
SK285684B6 (sk) 2007-06-07
PT872487E (pt) 2007-01-31
TW490469B (en) 2002-06-11
CZ115698A3 (cs) 1998-11-11
EP0872487B1 (en) 2006-10-18
ATE342921T1 (de) 2006-11-15
US5804420A (en) 1998-09-08
PL192072B1 (pl) 2006-08-31
MY115583A (en) 2003-07-31
SK49798A3 (en) 1998-12-02
US6171825B1 (en) 2001-01-09
ZA983234B (en) 1998-10-22
JP4257685B2 (ja) 2009-04-22
HU224306B1 (hu) 2005-07-28
HK1018797A1 (en) 2000-01-07
HUP9800901A2 (hu) 1999-05-28
HU9800901D0 (en) 1998-07-28
JPH10295397A (ja) 1998-11-10
RU2222547C2 (ru) 2004-01-27
UA66340C2 (uk) 2004-05-17
CA2234215A1 (en) 1998-10-18
CZ295049B6 (cs) 2005-05-18
BRPI9801092B8 (pt) 2021-07-06
AU6198298A (en) 1998-10-22
NZ330183A (en) 1999-08-30

Similar Documents

Publication Publication Date Title
BRPI9801092A (pt) processo para a produção de fator recombinante viii e meio de cultura de célula.
BR0015374A (pt) Diferenciação hematopoiética de troncocélulas embriÈnicas humanas
RU98107565A (ru) Получение рекомбинантного фактора viii в среде, не содержащей белка
HUP0105052A2 (hu) Eljárások nukleinsav amplifikálására és szekvenálására
NZ516400A (en) Stable factor VIII compositions
BR0316882A (pt) Melhora na qualidade de produtos em processos de cultura de células de mamìferos para a produção de proteìnas
BR0008772B1 (pt) vetor de expressão, célula bacteriana ou fúngica cultivada, processos para expandir in vitro células hematopoiéticas e progenitores de células hematopoiéticas, e para detectar a presença de rna de ligando zalfa11 e de ligando zalfa 11 in vitro em uma amostra biológica.
BR0108507A (pt) Cultivo livre de soro de células-tronco embriÈnicas de primatas
JPH10295397A5 (pt)
DK0799058T3 (da) Forbedringer af eller med hensyn til endometriefunktion
DK1137808T3 (da) Fremgangsmåde til fremstilling af rekombinante celler
DE69119256D1 (de) Kathodenstromsammler-Werkstoff für Festkathode-Zelle
ATE384079T1 (de) Marker für stammzellen und dessen verwendung
Chen et al. Recent advances on drawing technology of ultra-fine steel tire cord and steel saw wire
EP0758681A3 (en) Inhibition of the transformation of the cells with increased purine metabolic enzyme activity
SE8405681L (sv) Forfarande for utfellning av hardkrom pa en metallegering ur en vattenhaltig, kromsyra och svavelsyra innehallande elektrolyt
Lai et al. An evaluation of paramagnetic broadening agents for spin probe studies of intact mammalian cells
ES8307930A1 (es) Un metodo para depositar estano metalico brillante sobre un sustrato.
BR9905868A (pt) Procedimento de cultivo massivo de células de mamìfero para a obtenção de eritropoetina humana, recombinante e a eritropoetina humana recombinante obtida com tal procedimento
KR930016540A (ko) 신규의 미생물 및 이를 사용한 d-비오틴의 제조방법
EP1176194A4 (en) CELL CULTIVATION PROCEDURE
TH35885B (th) การเตรียมรีคอมบิเเน้นท์ (Recombinant) แฟคเตอร์ VIII ในอาหารเพาะเลี้ยงที่ปราศจากโปรตีน
ATE305988T1 (de) Einrichtung für die elektrolytische abscheidung von gold oder goldlegierungen
ES8302802A1 (es) Un metodo para la electrodeposicion de un deposito de niquel semibrillante, ductil y exento de tension.
ATE288476T1 (de) Herstellung von proteinen

Legal Events

Date Code Title Description
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/04/2013, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/04/98, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 25A ANUIDADE.

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 02/04/2023

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2718 DE 07/02/2023 POR TER SIDO INDEVIDA.